Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds

被引：11

作者：

Riether, Doris ^{[2
]}

Zindell, Renee ^{[1
]}

Wu, Lifen ^{[1
]}

Betageri, Raj ^{[1
]}

Jenkins, James E. ^{[3
]}

Khor, Someina ^{[3
]}

Berry, Angela K. ^{[1
]}

Hickey, Eugene R. ^{[1
]}

Ermann, Monika ^{[3
]}

Albrecht, Claudia ^{[4
]}

Ceci, Angelo ^{[2
]}

Gemkow, Mark J. ^{[4
]}

Nagaraja, Nelamangala V. ^{[1
]}

Romig, Helmut ^{[2
]}

Sauer, Achim ^{[2
]}

Thomson, David S. ^{[1
]}

机构：

[1] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA

[2] Boehringer Ingelheim Pharma GmbH & Co KG, D-88397 Biberach An Der Riss, Germany

[3] Evotec UK Ltd, Abingdon OX14 4RZ, Oxon, England

[4] Evotec AG, D-22419 Hamburg, Germany

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2015年 / 25卷 / 03期

关键词：

Cannabinoid receptor 2 (CB2); Proline; Metabolic stability; Solubility; Pharmacokinetic properties; CANNABINOID RECEPTOR; NEUROPATHIC PAIN; EXPRESSION; EFFICACY; AFFINITY; LIGANDS; SYSTEM;

D O I：

10.1016/j.bmcl.2014.12.019

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Through a ligand-based pharmacophore model (S)-proline based compounds were identified as potent cannabinoid receptor 2 (CB2) agonists with high selectivity over the cannabinoid receptor 1 (CB1). Structure-activity relationship investigations for this compound class lead to oxo-proline compounds 21 and 22 which combine an impressive CB1 selectivity profile with good pharmacokinetic properties. In a streptozotocin induced diabetic neuropathy model, 22 demonstrated a dose-dependent reversal of mechanical hyperalgesia. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：581 / 586

页数：6

共 50 条

[1] Selective CB2 receptor agonists. Part 3: The optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model
Bartolozzi, Alessandra
Cirillo, Pier Francesco
Berry, Angela K.
Hickey, Eugene R.
Thomson, David S.
Wu, Lifen
Zindell, Renee
Albrecht, Claudia
Ceci, Angelo
Gemkow, Mark J.
Nagaraja, Nelamangala V.
Romig, Helmut
Sauer, Achim
Riether, Doris
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 587 - 592
[2] Arylsulfonamide CB2 receptor agonists:: SAR and optimization of CB2 selectivity
Ermann, Monika
Riether, Doris
Walker, Edward R.
Mushi, Innocent F.
Jenkins, James E.
Noya-Marino, Beatriz
Brewer, Mark L.
Taylor, Malcolm G.
Amouzegh, Patricia
East, Stephen P.
Dymock, Brian W.
Gemkow, Mark J.
Kahrs, Andreas F.
Ebneth, Andreas
Loebbe, Sabine
O'Shea, Kathy
Shih, Daw-Tsun
Thomson, David
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (05) : 1725 - 1729
[3] Benzopyrans as selective estrogen receptor β agonists (SERBAs).: Part 2:: Structure-activity relationship studies on the benzopyran scaffold
Richardson, Timothy I.
Norman, Bryan H.
Lugar, Charles W.
Jones, Scott A.
Wang, Yong
Durbin, Jim D.
Krishnan, Venkatesh
Dodge, Jeffrey A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (13) : 3570 - 3574
[4] Design, synthesis, and structure-activity relationships of diindolylmethane derivatives as cannabinoid CB2 receptor agonists
Mahardhika, Andhika B. B.
Ressemann, Anastasiia
Kremers, Sarah E. E.
Castanheira, Mariana S. Gregorio S.
Schoeder, Clara T. T.
Mueller, Christa E. E.
Pillaiyar, Thanigaimalai
ARCHIV DER PHARMAZIE, 2023, 356 (03)
[5] 2-Amino-5-aryl-pyridines as selective CB2 agonists: Synthesis and investigation of structure-activity relationships
Gleave, Robert J.
Beswick, Paul J.
Brown, Andrew J.
Giblin, Gerard M. P.
Haslam, Carl P.
Livermore, David
Moses, Andrew
Nicholson, Neville H.
Page, Lee W.
Slingsby, Brian
Swarbrick, Martin E.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (23) : 6578 - 6581
[6] Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor
Han, Shuang
Zhang, Fei-Fei
Qian, Hai-Yan
Chen, Li-Li
Pu, Jian-Bin
Xie, Xin
Chen, Jian-Zhong
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 93 : 16 - 32
[7] 2-arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists.: Part 1:: Discovery of CB2 receptor selective compounds
Kai, Hiroyuki
Morioka, Yasuhide
Murashi, Takarni
Morita, Koichi
Shinonome, Satorni
Nakazato, Hitoshi
Kawamoto, Keiko
Hanasaki, Kohji
Takahashi, Furniyo
Mihara, Shin-ichi
Arai, Tohko
Abe, Kohji
Okabe, Hirosh
Baba, Takahiko
Yoshikawa, Takayoshi
Takenaka, Hideyuki
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (14) : 4030 - 4034
[8] Development of fluorinated CB2 receptor agonists for PET studies
Lueg, Corinna
Schepmann, Dirk
Guenther, Robert
Brust, Peter
Wuensch, Bernhard
BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (23) : 7481 - 7498
[9] Selective CB2 receptor agonists. Part 1: The identification of novel ligands through computer-aided drug design (CADD) approaches
Hickey, Eugene R.
Zindell, Renee
Cirillo, Pier F.
Wu, Lifen
Ermann, Monika
Berry, Angela K.
Thomson, David S.
Albrecht, Claudia
Gemkow, Mark J.
Riether, Doris
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 575 - 580
[10] Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists
Han, Sangdon
Thatte, Jayant
Buzard, Daniel J.
Jones, Robert M.
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (21) : 8224 - 8256

← 1 2 3 4 5 →